Adaptive Biotechnologies Corp (ADPT)

NASDAQ
36.49
-2.73(-6.96%)
After Hours
37.00
+0.51(+1.40%)
- Real-time Data
  • Volume:
    521,131
  • Bid/Ask:
    36.50/39.73
  • Day's Range:
    36.42 - 39.03

ADPT Overview

Prev. Close
39.22
Day's Range
36.42-39.03
Revenue
133.43M
Open
38.72
52 wk Range
29.73-71.25
EPS
-1.24
Volume
521,131
Market Cap
5.14B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
602,372
P/E Ratio
-
Beta
-
1-Year Change
-24.44%
Shares Outstanding
140,765,849
Next Earnings Date
Nov 16, 2021
What is your sentiment on Adaptive Biotechnologies Corp?
or
Market is currently closed. Voting is open during market hours.

Adaptive Biotechnologies Corp News

Adaptive Biotechnologies Corp Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Adaptive Biotechnologies Corp Company Profile

Adaptive Biotechnologies Corp Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Read More
  • how can this valuation (5bn vs. 100m revenues) be justified?
    0
    • with the help of GlaxoSmithKline buy
      0
      • they will be the ones who will find a vaccine.buy
        0
        • is this just from the virus or is this a buy?
          0
          • Hoy interpretais que es buen momento para comprar? .  Después de vela bajista envolvente hay vela alcosta. Entendeís que puede tener tendencia alcista hasta 43,75$. Escribe tus pensamientos respecto al Adaptive Biotechnologies Corp
            0
            • Going to drop like a rock this week! Already 340 million in debt in just the first quarter of this year alone.
              1
              • sweet
                1
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.